Repurposing Dipyridamole in Niemann Pick Type C Disease: A Proof of Concept Study

Abstract

Niemann Pick type C disease (NPC) is a rare disorder characterized by lysosomal lipid accumulation that damages peripheral organs and the central nervous system. Currently, only miglustat is authorized for NPC treatment in Europe, and thus the identification of new therapies is necessary. The hypothesis addressed in this study is that increasing adenosine levels may represent a new therapeutic approach for NPC. In fact, a reduced level of adenosine has been shown in the brain of animal models of NPC; moreover, the compound T1-11, which is able to weakly stimulate A2A receptor and to increase adenosine levels by blocking the equilibrative nucleoside transporter ENT1, significantly ameliorated the pathological phenotype and extended the survival in a mouse model of the disease. To test our hypothesis, fibroblasts from NPC1 patients were treated with dipyridamole, a clinically-approved drug with inhibitory activity towards ENT1. Dipyridamole significantly reduced cholesterol accumulation in fibroblasts and rescued mitochondrial deficits; the mechanism elicited by dipyridamole relies on activation of the adenosine A2AR subtype subsequent to the increased levels of extracellular adenosine due to the inhibition of ENT1. In conclusion, our results provide the proof of concept that targeting adenosine tone could be beneficial in NPC.

Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat

“…NPC, caused by mutations in the NPC1 gene, involves the accumulation of lipids in the liver, spleen, and brain, leading to progressive neurological symptoms. Pepponi and co-workers, finding evidence that NPC mice show reduced extracellular adenosine levels [ 74 ], focused their attention on the possibility of increasing adenosine levels by inhibiting its equilibrative nucleoside transporter (ENT1) [ 75 ]. To this end, they used dipyridamole, an antiplatelet aggregation known to inhibit ENT1.…”